Drugs / Tonapofylline
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00858156 | Apr → Aug 2009 | — | Biogen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00745316 | Feb 2009 → Jan 2010 | heart failure, impaired renal function disease | Biogen | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00709865 | Jul 2008 → Oct 2009 | congestive heart failure, impaired renal function disease | Biogen | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tonapofylline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00709865 ↗ |
| Known as | BG9928 | “tonapofylline (BG9928)” NCT00745316 ↗ |
| Known as | Tonapofilina | ChEMBL registry synonym — accepted as the source's own label CHEMBL414157 ↗ |
| Action | Inhibit | “Selective Adenosine A1 Receptor Antagonist” NCT00745316 ↗1“Adenosine A1 receptor antagonist” CHEMBL414157 ↗ |
| Modality | Small molecule | — CHEMBL414157 ↗ |
| Route | Oral | “Oral Tonapofylline - 2 capsules bid” NCT00745316 ↗ |
| Target | ADORA1 | “Adenosine A1 receptor antagonist” CHEMBL414157 ↗ |